hydroxyurea   Click here for help

GtoPdb Ligand ID: 6822

Synonyms: Droxia® | Hydrea® | hydroxycarbamide | Siklos® | SQ-1089 | Xromi®
Approved drug PDB Ligand
hydroxyurea is an approved drug (FDA (1967), EMA (2007))
Compound class: Synthetic organic
Comment: Inhibits ribonucleoside-diphosphate reductase (RR1).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 3
Rotatable bonds 1
Topological polar surface area 75.35
Molecular weight 76.03
XLogP -1.61
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES NC(=O)NO
Isomeric SMILES NC(=O)NO
InChI InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
InChI Key VSNHCAURESNICA-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Approved as either hydroxyurea or hydroxycarbamide, this drug is used to treat melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. In the US, the FDA has approved hydroxyurea to treat sickle cell anemia in adults, as shown by the presence of hemoglobin S. The FDA has subsequently granted orphan designation for the treatment of sickle cell disease in pediatric and young adult patient groups (2005-2015). The EMA granted hydroxyurea orphan designation as a treatment for sickle cell syndrome in 2003, and full approval for this indication was granted in 2019.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase
External links Click here for help